A small wool blanket wrapped around a baby who is stillborn or lost during pregnancy can make a significant difference in an acute situation of loss. This is shown in an artistic research dissertation from the University of Gothenburg.

Three faculty researchers from The University of Texas at San Antonio were celebrated with the inaugural Texas Innovation Award, a new statewide award recognizing leadership in translating academic research into real-world impact.

A phase 2 clinical trial showed burosumab, a targeted antibody therapy, safely restored phosphate balance in children and adults with fibrous dysplasia, a rare bone disorder associated with fractures and deformities. The therapy reduced abnormal bone turnover markers and improved mobility in severely affected children, including independent walking after full-time wheelchair use. The findings suggest that inhibition of fibroblast growth factor-23 may help reduce disability and improve physical function in patients with phosphate-wasting skeletal disease.

Osteosarcoma is an aggressive bone cancer characterized by high rate of recurrence and metastasis. In a new study, researchers show that restoring the RNA-editing enzyme adenosine deaminase acting on RNA 2 (ADAR2) slows tumor growth, reduces invasion, promotes bone-like differentiation, and improves chemotherapy sensitivity in cell and mouse models. The findings identify IGFBP7 RNA editing as a key mechanism underlying these effects, highlighting a potential differentiation-based treatment strategy for pediatric patients with bone cancer.